Acadia Pharmaceuticals Inc (NASDAQ: ACAD). Extremely significant positive changes in investment behavior have recently occurred: the stock rose on very heavy volume, and its shorter term price trend turned up.
Notable positive changes in Acadia Pharmaceuticals Inc (NASDAQ: ACAD) fundamentals have recently occurred: significant quarterly earnings acceleration occurred, and significant quarterly sales acceleration occurred.
In light of these very positive signals we are reviewing our current Overall Rating of F. We would view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
Acadia Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing complementary signals. Acadia Pharmaceuticals has a slightly negative Power Rating of 37 and a very low Appreciation Score of 13, leading to the Lowest Value Trend Rating.
Recent Price Action
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stock closed at $18.76 on 12/9/24 after a very large increase of 8.6%. Moreover, this advance was accompanied by exceptionally high trading volume at 253% of normal. The stock has been weak relative to the market over the last nine months but has risen 15.0% during the last week.
Be the first to comment